Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5709986 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| Phosphoric Acid SCHEMBL18249308 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| Phosphoric Acid SCHEMBL7977953 | 1.00 | TK1 (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL925743 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL22992337 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL14596607 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL13286394 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL762579 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL23485 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM | |
| SCHEMBL14421795 | 0.95 | LMNA (0.58) | TK1LMNATSHRALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936522-B | Novel anti-thymidine kinase antibody | 豪夫迈·罗氏有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023143247-A1 | LINKER FOR CHARACTERIZING SEQUENCING OF TARGET POLYNUCLEOTIDE, CONSTRUCT, METHOD, AND USE | 成都齐碳科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-111936522-A | Novel anti-thymidine kinase antibodies | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-110520128-A | Compositions and methods for treating complications and diseases associated with von Willebrand factor | BAND THERAPEUTICS LLC | 2019-11-29 | — | — | CN | disclosed |
| CN-110168104-A | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES USING NANOPORES | 牛津纳米孔技术公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110121562-A | Method of producing a composite material | 牛津纳米孔技术公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-110088299-A | Nanopore-directed nucleic acid detection methods | 牛津纳米孔技术公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-109328192-A | Labeled polynucleotide composition and the method for nucleic acid sequencing | 宽腾矽公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-109312401-A | The nano-pore sequencing method of the nucleic acid of connection | 牛津纳米孔技术公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109219665-A | Method | 牛津纳米孔技术公司 | 2019-01-15 | — | — | CN | disclosed |
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | COVALENT BIOSCIENCE INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| EP-1610808-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | University of Texas Medical School (US) | 2006-01-04 | — | — | EP | disclosed |
| CN-1216883-C | Synthesis of anticancer medicine raltiprexed | UNIV CAPITAL NORMAL (CN) | 2005-08-31 | — | — | CN | disclosed |
| WO-2004087059-A2 | COVALENT ATTACHMENT OF LIGANDS TO NUCLEOPHILIC PROTEINS GUIDED BY NON-COVALENT BINDING | THE UNIVERSITY OF TEXAS (US) | 2004-10-14 | — | — | WO | disclosed |
| CN-1486985-A | Synthesis of anticancer medicine Raltiprexed | 首都师范大学 | 2004-04-07 | — | — | CN | disclosed |
| CN-1432069-A | Degradable nucleic acid probes and methods for nucleic acid detection | NAXCOR (US) | 2003-07-23 | — | — | CN | disclosed |
| US-5780617-A | PHOSPHORYLATION OF A PHOSPHATIDES WITH A NUCLEOTIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0531452-A4 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0531452-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | NeXstar Pharmaceuticals, Inc. (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179083-A1 | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding | FABP1, FPR1, ADGRF1 | ADRA1A 1438/4885TK1 1556/4885LMNA 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.